Sign in

Amendments › HF 978

Amendment S-5119 to HF 978

Relating to the production and administration of psilocybin, and providing penalties

Never voted on

Filed March 19, 2026 in the Senate by

In plain words

AI summary This amendment changes the effective year of the bill and updates the medical cannabidiol board to include members with expertise in psilocybin, mushroom cultivation, and research manufacturing. It also requires that patients receiving psilocybin have verified post-traumatic stress disorder and establishes rules for transferring the existing cannabidiol board's duties, funds, and files to the new licensing board.1

What it changes

  1. Page 1, line 1, by striking “2025” and inserting “2026”
  2. Page 1, after line 7 by inserting: “Sec. ___. Section 124E.2, subsection 10, Code 2026, is amended to read as follows:
  3. “Medical cannabidiol” means any pharmaceutical grade cannabinoid found in the plant Cannabis sativa L. or Cannabis indica or any other preparation thereof that is delivered in a form recommended by the Iowa medical cannabidiol controlled substances advisory and licensing board, approved by the board of medicine, and adopted by the department pursuant to rule. Sec. ___. Section 124E.5, subsection 1, paragraph a, Code 2026, is amended to read as follows: a. A An Iowa medical cannabidiol controlled substances advisory and licensing board is created consisting of eight practitioners representing the fields of neurology, pain management, gastroenterology, oncology, psychiatry, pediatrics, family medicine, and pharmacy, and one representative from law enforcement , one member with knowledge of psilocybin, one member who is a chemist or researcher with expertise in the nutraceutical manufacturing industry, one member who has a background in fungus or mushroom cultivation and processing, and one member who is a chemist or researcher with experience in manufacturing and who is associated with a research university . Sec. ___. Section 124E.5, subsection 1, Code 2026, is amended by adding the following new paragraph: NEW PARAGRAPH . e. Members of the Iowa medical controlled substances advisory and licensing board shall serve for four years and may be reappointed. Sec. ___. Section 124E.5, subsection 2, Code 2026, is amended to read as follows:
  4. The Iowa medical cannabidiol controlled substances advisory and licensing board shall convene as necessary. Sec. ___. Section 124E.5, subsection 3, unnumbered paragraph 1, Code 2026, is amended to read as follows: The duties of the Iowa medical cannabidiol controlled substances advisory and licensing board shall include but not be limited to the following: Sec. ___. Section 124E.5, subsections 4 and 5, Code 2026, are amended to read as follows:
  5. Recommendations made by the Iowa medical cannabidiol controlled substances advisory and licensing board pursuant to subsection 3 , paragraphs “b” and “e” , shall be made to the board of medicine for consideration, and if approved, shall be adopted by the board of medicine by rule.
  6. On or before January 1 of each year , beginning January 1, 2018 , the Iowa medical cannabidiol controlled substances advisory and licensing board shall submit a report detailing the activities of the board. Sec. ___. Section 124E.11, subsection 2, paragraph c, Code 2026, is amended to read as follows: c. Establish the form and quantity of medical cannabidiol allowed to be dispensed to a patient or primary caregiver pursuant to this chapter as appropriate to serve the medical needs of patients with debilitating medical conditions, subject to recommendation by the Iowa medical cannabidiol controlled substances advisory and licensing board and approval by the board of medicine.”
  7. Page 2, line 14, by striking “psilocybin production”
  8. Page 2, by striking lines 15 and 16 and inserting “Iowa medical controlled substances advisory and licensing board created pursuant to section 124E.5.”
  9. Page 5, lines 22 and 23, by striking “Psilocybin production establishment licensing board” and inserting “Licensing board —— duties”
  10. By striking page 5, line 24, through page 6, line
  12. Page 6, by striking line 27 and inserting: “
  13. The licensing board shall meet as necessary to do”
  14. Page 6, by striking line 34 and inserting: “
  15. The licensing board shall hold a public hearing to review”
  16. Page 7, by striking lines 3 and
  18. Page 7, line 19, before “board” by inserting “licensing”
  19. Page 8, line 17, before “board” by inserting “licensing”
  20. Page 8, line 19, before “board” by inserting “licensing”
  21. Page 10, line 20, by striking “2026” and inserting “2027”
  22. Page 23, line 35, by striking “2026” and inserting “2027”
  23. Page 25, after line 8 by inserting: “d. Verified that the patient has post-traumatic stress disorder.”
  24. Page 29, line 34, after “provider” by inserting “pursuant to section 124F.22”
  25. Page 32, line 30, by striking “2025” and inserting “2026”
  26. Page 33, line 14, by striking “2028” and inserting “2029”
  27. Page 35, line 12, by striking “2026” and inserting “2027”
  28. Page 35, after line 12 by inserting: “Sec. ___. TRANSITION PROVISIONS.
  29. The sections of this Act amending section 124E.5 shall not affect the appointment or terms of office of members currently serving on the medical cannabidiol board.
  30. Any license issued by the medical cannabidiol board in effect on the effective date of this Act shall continue in full force and effect until expiration or renewal.
  31. Any unobligated and unencumbered funds in any account or fund under the control of the medical cannabidiol board shall be transferred to the control of the Iowa medical controlled substances advisory and licensing board.
  32. Any cause of action, statute of limitation, or administrative action relating to or initiated by the medical cannabidiol board shall not be affected as a result of this Act and shall apply to the Iowa medical controlled substances advisory and licensing board.
  33. All client and organizational files in the possession of the medical cannabidiol board shall become the property of the Iowa medical controlled substances advisory and licensing board.”
  34. Title page, line 2, after “psilocybin” by inserting “to persons with post-traumatic stress disorder and changes to the medical cannabidiol board”
  35. By renumbering as necessary.

Official amendment (PDF) · In the Bill Book